CommercialCoverageMedium impact
06.02.01l, Lyme Disease: Diagnosis and Intravenous (IV) Antibiotic Therapy
Independence Blue Cross·Infectious Disease, Family Medicine, Internal Medicine +1 more·Medical Policy
Effective date
Dec 29, 2025
We identified it
Jun 19, 2026
Summary
IBX has updated their medical policy for Lyme Disease diagnosis and IV antibiotic therapy, affecting medical necessity criteria and medical coding requirements. This policy change impacts how providers document, code, and justify IV antibiotic treatments for Lyme disease patients.
Action Required
By December 29, 2025: Billing team must review updated medical necessity criteria for Lyme disease IV antibiotic therapy claims. Update documentation requirements in EMR templates to ensure proper justification for IV treatments. Verify coding guidelines are current in billing system. Claims not meeting new medical necessity criteria may be denied.